Everence Capital Management Inc. reduced its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,928 shares of the biopharmaceutical company’s stock after selling 916 shares during the period. Everence Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $2,263,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Delphi Private Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $108,000. Atlantic Trust LLC purchased a new stake in Bristol-Myers Squibb during the 2nd quarter worth approximately $111,000. Massey Quick Simon & CO. LLC increased its stake in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the period. Blue Chip Partners Inc. increased its stake in Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 15 shares during the period. Finally, Horan Capital Advisors LLC. purchased a new stake in Bristol-Myers Squibb during the 3rd quarter worth approximately $122,000. 71.55% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Co (BMY) traded down $0.33 during trading hours on Wednesday, reaching $66.35. The company had a trading volume of 3,312,683 shares, compared to its average volume of 7,973,780. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05. The firm has a market capitalization of $109,420.00, a P/E ratio of 28.09, a P/E/G ratio of 2.07 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter in the prior year, the business earned $0.63 earnings per share. The company’s revenue was up 3.9% on a year-over-year basis. equities analysts predict that Bristol-Myers Squibb Co will post 3.2 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a dividend yield of 2.41%. Bristol-Myers Squibb’s dividend payout ratio is 67.80%.
A number of research firms recently commented on BMY. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price on the stock. in a research report on Tuesday, January 16th. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, January 19th. Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Monday, December 11th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $66.30.
In other news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is currently owned by corporate insiders.
WARNING: “Bristol-Myers Squibb Co (NYSE:BMY) Holdings Cut by Everence Capital Management Inc.” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://ledgergazette.com/2018/03/14/bristol-myers-squibb-co-bmy-position-trimmed-by-everence-capital-management-inc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.